TIBC study: A multiple-centre Phase 2 trial comparing the efficacy of 2-Iminobiotin (2-IB) treatment to standard care in neonates with gestational age of ≥36 weeks with moderate to severe perinatal asphyxia in DR Congo.

Trial Profile

TIBC study: A multiple-centre Phase 2 trial comparing the efficacy of 2-Iminobiotin (2-IB) treatment to standard care in neonates with gestational age of ≥36 weeks with moderate to severe perinatal asphyxia in DR Congo.

Not stated
Phase of Trial: Phase II

Latest Information Update: 27 Sep 2016

At a glance

  • Drugs 2-iminobiotin (Primary)
  • Indications Asphyxia
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Acronyms TIBC
  • Sponsors Neurophyxia
  • Most Recent Events

    • 27 Sep 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top